WINREVAIR

all catalysts(0)

nothing on the calendar yet

News(6)

• BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
  BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
  biospace · 2d ago
• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
  Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
  biopharma_dive · 2mo ago
• GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
  GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…
  fiercebiotech · 2mo ago
• After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
  After signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH) candidate seralutinib in 2024, Gossamer Bio has ended the collaborat…
  fiercebiotech · 2mo ago
• Acceleron leaders and Westlake jumpstart new IPF biotech
  After success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million Series A round,…
  endpoints · 4mo ago
• Merck still sees ‘compelling’ outlook for Terns leukemia drug
  Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
  biopharma_dive · 5mo ago